Peringkat dalam Saham
#18692
Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused... Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused on developing novel therapeutic compositions derived from endogenous metabolic modulators. These aim to address complex diseases and improve overall health. The company's primary drug candidates are AXA1665 and AXA1125. AXA1665 is currently undergoing Phase 2 clinical trials, where it is being evaluated for its potential to lower the risk of recurrent overt hepatic encephalopathy. Meanwhile, AXA1125 is progressing through multiple trials: a Phase 2b study targeting non-alcoholic steatohepatitis (NASH) treatment, and a Phase 2a study exploring its efficacy as a therapy for Long COVID patients. Founded in 2008, the entity initially operated as Newco LS16, Inc. before officially adopting the name Axcella Health Inc. in June 2016. Its operations are headquartered in Cambridge, Massachusetts.
Harga Saham
$4.58
Terakhir disinkronkan: 2025-02-06
Kapitalisasi Pasar
$189.73M
Perubahan (1 tahun)
0.00%
Perdagangan Axcella Health Inc. (AXLA)
Harga AXLA dengan kapitalisasi pasar B
Kapitalisasi pasar dari Axcella Health Inc.(AXLA)
Kapitalisasi Pasar: $189.73M
Per August 2026, Axcella Health Inc. memiliki kapitalisasi pasar sebesar $189.73M. Ini menjadikan Axcella Health Inc. sebagai perusahaan 18692nd paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Axcella Health Inc. dari 2019 hingga 2026
AXLA dibandingkan dengan 5 teratas stocks paling populer
| Harga AXLA |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.088T
|
+2,681,511.29%
|
|
|
|
|
$4.629T
|
+2,439,708.64%
|
|
|
|
|
$4.118T
|
+2,170,118.93%
|
|
|
|
|
$3.687T
|
+1,943,019.60%
|
|
|
|
|
$2.800T
|
+1,475,480.92%
|
